"Is it true that it works for anxiety and PTSD? Latest research pours cold water on the hype surrounding medical cannabis."

Medical cannabis is often referred to as the "last resort" nowadays. For those who have not seen sufficient improvement with antidepressants or anti-anxiety medications, have long suffered from sleep disorders, or are troubled by PTSD flashbacks and tension, cannabis-derived components appear to be a potential alternative different from existing treatments. In fact, the scope of prescriptions is expanding in various countries, and numerous testimonials such as "I got my life back" and "I can sleep now" can be found online.

However, in contrast to this enthusiasm, science remains quite cautious. An article distributed by Fehmarn24 in Germany reported, based on a large-scale review by a research team from the University of Sydney, that "the benefits of medical cannabis for mental disorders are very limited." According to the original article, the research team scrutinized 54 international clinical trials from 1980 to 2025, involving a total of 2,477 participants. The findings indicated a harsh assessment that there is no strong evidence supporting the efficacy of cannabinoid formulations for anxiety disorders, PTSD, psychotic disorders, opioid use disorders, and the like.

The attention garnered by this study is not merely because it concluded "it didn't work." The issue surrounding medical cannabis is that societal expectations tend to outpace scientific validation, with the expansion of prescriptions and usage advancing faster than scientific examination. Lead author Jack Wilson and his team pointed out that while medical cannabis shows potential for some conditions, there is a lack of high-quality evidence in the fields of mental disorders and addiction. Particularly concerning depression, according to Reuters, no randomized controlled trials could be confirmed. In other words, before determining "whether it works or not," the foundation for proper verification is thin.

It is important to note that this study does not claim that "cannabis is completely useless." The analysis showed limited improvement signals for conditions such as tics in Tourette syndrome, sleep disorders, some symptoms related to autism spectrum disorder, and withdrawal symptoms from cannabis use disorder. However, the research team themselves emphasized that the quality of this evidence is low. Factors such as small sample sizes, short durations, potential biases, and funding source biases could lead to apparent effects that cannot be generalized in clinical practice.

The problem is that such "limited possibilities" are often misinterpreted in society as "effective for everything." Medical cannabis has shown certain usefulness in areas such as pain, epilepsy, and spasticity associated with multiple sclerosis. However, these achievements do not directly translate to the psychiatric field. Symptoms related to the brain and mind are susceptible to self-reporting influences, and expectations, anxiety, short-term euphoria, and sedative effects can easily sway results. Whether the sense of relief felt today leads to recovery weeks or months later is something that must be strictly monitored.

Moreover, the research team touched on not only the "limited benefits" but also the "potential harms." These include the worsening of psychotic symptoms, the risk of cannabis use disorder, and the danger of delaying the initiation of established effective treatments. Even if the individual feels "I could reduce my medication" or "I could at least sleep," in the long run, it may distance them from recovery. This point is also applicable to psychiatric treatment in general. Immediate relief from distress and improvement of the disease itself are not necessarily the same.

On the other hand, there are dissenting opinions regarding this study. In the Fehmarn24 article, Kirsten Müller-Vahl from Hannover Medical School, an expert in medical cannabis research, questioned the way the review was summarized. The clear point of contention is whether THC and CBD should be evaluated together. Although both are often referred to as "cannabis-derived components," their effects on mental symptoms are not identical. She suggests that there are studies indicating the reduction of social anxiety with CBD or the alleviation of PTSD symptoms with THC alone or in combination with CBD, viewing the warnings as too strong.

This criticism cannot be overlooked. The debate over medical cannabis tends to polarize proponents and opponents into broad arguments, but the actual issues are more nuanced. Which component, in what quantity, for which patient, over what period, and evaluated by which criteria? Whether it's smoking or oil, a single agent or a combination, the results can vary. While review studies are suitable for presenting a large map, they also have the weakness of smoothing out fine differences. Therefore, the conclusion of this study should be read not as "medical cannabis has zero psychiatric value," but rather as "there is not enough solid evidence to widely recommend it at this point."

Nevertheless, the significance of this study for society is not small, because in reality, usage has already spread ahead. In Germany, medical cannabis has been legally prescribable since 2017, and in April 2024, it was removed from the scope of the Narcotics Act. Subsequently, the German government has increased concerns about abusive practices, moving to restrict prescriptions through online consultations and mail-order sales. According to government explanations, the import volume for medical purposes in the first half of 2025 increased by over 400% compared to the same period the previous year, reaching about 80 tons. Even just looking at the numbers, it is clear that changes in the system have rapidly expanded the market.

The issue that arises here is the often-overlooked but obvious point that "the expansion of the system" and "proof of effectiveness" are separate matters. The market expands with expectations. Patients move with hope. Clinics and businesses have economic incentives. However, medicine should inherently be a system that interjects evidence into that. If expansion continues solely because "patients desire it" or "some people feel better," those for whom it is ineffective, those who worsen, and those who approach dependency may be left behind.

So, how is this study perceived on social media? Tracing the reactions online reveals three main trends.

The first is the cautious group that perceives it as "the scientific evidence was indeed weak." In medical and scientific communities, subjective evaluations like mood improvement and anxiety reduction are seen as susceptible to placebo effects, and it is considered natural to verify them through randomized controlled trials. There is also a view that in mental symptoms, even if there is a short-term sense of calm, it may worsen the long-term course. For this group, the current study is welcomed as "material to once again reset the image-driven debate."

The second is the response from a personal perspective: "I respect the research, but it differs from my own experience." Among public posts, there are voices describing improvements in sleep and recovery of life functions, and particularly among those who suffered from the side effects of existing drugs, medical cannabis is strongly positioned as an "effective treatment." These voices do not so much deny the research results themselves but rather suggest a feeling that "there may be a few people for whom it works, who are cut off by average values." On social media, this strong sense of experience often manifests as opposition to statistical conclusions.

The third is the methodological skepticism: "Isn't it too much to mix THC and CBD, types of mental disorders, dosages, and administration methods in the discussion?" This criticism overlaps with that of experts. For example, even within anxiety disorders, generalized anxiety disorder and social anxiety disorder are different in nature, and with PTSD, the effects on sleep disorders or nightmares need to be considered separately from the effects on the condition itself. On social media, there are quite a few reactions that the review study's conclusion of "all together weak" is "too roughly summarized."

When these three reactions are lined up, the true nature of the conflict over medical cannabis becomes apparent. One side says, "Without evidence of efficacy, it should not be recommended lightly." The other side says, "I was helped, so don't dismiss it as ineffective." And the third position says, "The way the questions are posed is crude." Each has a point. Therefore, this topic does not end with a simple pros and cons.

However, what must not be forgotten here is that the ultimate standard in medicine is whether it can be "reproduced." An individual's effective experience is important, but if it cannot be safely reproduced for another person, it is unlikely to become a standard treatment. Conversely, if in the future, CBD-centric formulations or specific PTSD symptoms are shown to be effective through higher-quality trials, the evaluation could change. This study merely stated that "there is not as much evidence as widely discussed at present," rather than condemning it as "forever useless."

Rather, the real question is what we seek from medicine. Is it a narrative that supports hope, or strict evidence? In reality, neither alone is sufficient. Patients need relief, and medicine needs verification. The debate over medical cannabis reflects the modern medical challenge of how to balance these two.

The review's indication is a sign to pause amidst the boom's fervor. At present, medical cannabis for mental disorders undeniably carries "expectation ahead." Therefore, what is needed is neither outright denial nor complete praise. Which components are effective for which symptoms under what conditions? The next step is research that carefully delineates these aspects. The voices on social media paradoxically indicate this necessity. If there are so many strong personal experiences of efficacy, they should be rigorously examined, and if there are people for whom it is ineffective or worsens, those boundaries must also be identified. What is needed beyond the fervor is a more detailed and calm discussion.

Source URL

・Fehmarn24/dpa. Referenced to confirm the context of the University of Sydney team's review content, Müller-Vahl's criticism, and the tightening of German government regulations.
https://www.fehmarn24.de/welt/studie-kaum-nutzen-von-cannabis-bei-psychischen-leiden-zr-94221274.html

・Reuters article reporting the key points of the research. Used to confirm the lack of clear efficacy in anxiety disorders, PTSD, psychotic disorders, and opioid use disorders across 54 trials and 2,477 people, and the absence of RCTs for depression.
https://www.reuters.com/business/healthcare-pharmaceuticals/cannabis-shows-little-benefit-most-mental-disorders-data-review-finds-2026-03-16/

・Reprint page of an explanatory article by the author. Referenced to assist in understanding the research team's issues and points of discussion.
https://www.tolerance.ca/ArticleExt.aspx?ID=599481&L=en

・The Lancet Psychiatry article search results. Used to confirm the publication site of the review paper itself.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2826%2900015-5/fulltext

・FAQ from the German Federal Ministry of Health. Used to confirm that the import volume in the first half of 2025 increased from about 19 tons to about 80 tons, and the reasons for the review of the system.
https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/guv-21-lp/aend-medcang/faq-medcang

・Explanation page of the German Federal Parliament. Used to confirm the background of the bill for reviewing medical cannabis regulations.
https://www.bundestag.de/dokumente/textarchiv/2025/kw51-de-cannabis-1129260

・Example of public online reaction 1. Used as a reference to show the strong personal experiences of "I was helped" in response to the research report.
https://www.reddit.com/r/Biohackers/comments/1pkxw1d/review_of_medical_cannabis_use_finds_little/

・Example of public online reaction 2. Used as a reference for the cautious view of mood and anxiety effects in medical and scientific forums.
https://www.reddit.com/r/medicine/comments/u7w90g/cannabis_use_in_medicine/